Major bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes major bleeding compared with low molecular weight heparin (LMWH) (very low certainty).
2 findings from 1 review
Minor bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether aspirin (ASA) changes minor bleeding compared with low molecular weight heparin (LMWH) (very low certainty).
1 finding from 1 review
Minor bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether vitamin K antagonist (VKA) changes all‐cause mortality compared with low molecular weight heparin (LMWH) (very low certainty).
2 findings from 1 review
Symptomatic DVT · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether vitamin K antagonist (VKA) changes symptomatic deep vein thrombosis compared with low molecular weight heparin (LMWH) (very low certainty).
2 findings from 1 review
Pulmonary embolism · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether vitamin K antagonist (VKA) changes pulmonary embolism compared with low molecular weight heparin (LMWH) (very low certainty).
2 findings from 1 review
Major bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents
The review found no eligible studies for this question.
2 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Minor bleeding · ambulatory patients with multiple myeloma receiving immunomodulatory agents
It is very uncertain whether vitamin K antagonist (VKA) changes minor bleeding compared with low molecular weight heparin (LMWH) (very low certainty).
1 finding from 1 review
Minor bleeding ‐ not reported · ambulatory patients with multiple myeloma receiving immunomodulatory agents
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Overall mortality · DIC
1 finding from 1 review
Adverse events · DIC
It is very uncertain whether recombinant human soluble thrombomodulin changes adverse events compared with heparin (very low certainty).
1 finding from 1 review
Bleeding · DIC
1 finding from 1 review
Resolution of respiratory failure · DIC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Renal failure · DIC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Shock · DIC
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mortality from any cause (15‐day and 30‐day in‐hospital) · DIC
It is very uncertain whether human activated protein C changes mortality from any cause (15‐day and 30‐day in‐hospital) compared with heparin (very low certainty).
1 finding from 1 review
Overall mortality · DIC
1 finding from 1 review
Mortality from any cause (15‐day and 30‐day in‐hospital) · DIC
1 finding from 1 review
Adverse events · DIC
1 finding from 1 review
Bleeding · DIC
It is very uncertain whether dermatan changes bleeding compared with heparin (very low certainty).
1 finding from 1 review